Market Authorisation Update

Source: RNS
RNS Number : 9826J
Benchmark Holdings PLC
03 May 2022

3 May 2022


Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")


Ectosan® Vet

Variation to Marketing Authorisation enabling a second use of treatment water

An important milestone towards optimal efficiency of Benchmark's transformational sea lice solution


Benchmark (LSE: BMK), the aquaculture biotechnology company, is pleased to announce that it has been granted a variation to its Marketing Authorisation ("MA") for Ectosan® Vet  from the Norwegian Medicines Agency ("NoMA").


This variation to the MA enables the re-use of the treatment water for a second batch of fish, subject to water quality being maintained to the satisfaction of the prescribing veterinarian, therefore increasing the efficiency of treatments. This means a producer will be able to treat a salmon farm more efficiently with a solution that delivers more than 99% efficacy, promotes animal welfare, reduces mortality and protects the environment - driving sustainability in the industry.


This MA variation represents a further important step towards our goal of optimising the efficiency of our sea lice solution, and further trials are ongoing to support multiple re-use of treatment water. 


 Trond Williksen, CEO, commented:


"We are very pleased to have been granted a variation to the Marketing Authorisation from the Norwegian Medicines Agency. This represents an important milestone for the Company and for the industry. Ectosan® Vet and CleanTreat® is a much needed solution for the industry which continues to show excellent results with efficacy above 99% as well as good operational efficiency. It is the first medicinal solution brought to the Norwegian market in over ten years which addresses one of the biggest challenges in salmon production, while improving animal welfare, reducing mortality and protecting the environment."




Benchmark Holdings plc

Tel: 020 3696 0630

Trond Williksen, CEO

Septima Maguire, CFO

Ivonne Cantu, Investor Relations




Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black / Freddie Barnfield / Duncan Monteith






Katie Hunt/Charlie Protheroe/Fergal Bettridge-Boyd     

Tel: 020 3128 8990                   






About Benchmark 

Benchmark is a market leading aquaculture biotechnology company. Benchmark's mission is to drive sustainability in aquaculture by delivering products and solutions in genetics, advanced nutrition and health which improve yield, growth and animal health and welfare.

Through a global footprint in 26 countries and a broad portfolio of products and solutions, Benchmark addresses the major aquaculture species - salmon, shrimp, sea bass and bream, and tilapia,  in all the aquaculture regions around the world. Find out more at


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.